Neurogene Inc. (NGNE)
NASDAQ: NGNEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
NGNE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $517.69M
- EPS (TTM)
- -$5.04
- Dividend yield
- None
- 52-week range
- 15.93 – 43.66
- Day range
- 25.01 – 26.01
- Volume / Avg
- 114.07K / 248.09K
- Beta
- —
- Shares outstanding
- 20.01M
52-week range
NGNE stock today
On Oct 7, NGNE ended the session at $25.87, adding $0.42 (1.65%), versus the S&P 500's 0.22% decline. Trading was light, with 114.07K shares changing hands, about 46% of the average daily volume. At this level, NGNE sits in the middle of its 52-week range of $15.93 to $43.66: 40.7% below the high, set on Jul 9, 2026 and 62.4% above the low.
NGNE is up 25.6% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 10.2%. Neurogene has posted a net loss over the last twelve months (EPS of -$5.04), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Neurogene
Company profileNeurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Rachel L. McMinn Ph.D.
- Headquarters
- New York, NY
- Employees
- 131
- IPO year
- 2014
- Website
- neurogene.com
Analyst forecast
ForecastConsensus (9 analysts)
none
Avg. price target
$80.43+210.90%
- Strong buy 0
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Neurogene peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EOLSEvolus Inc. | 7.74 | +4.88% | $511.23M | vs NGNE |
| PBYIPuma Biotechnology Inc | 9.81 | +3.26% | $506.39M | vs NGNE |
| DRUGBright Minds Biosciences Inc. | 52.00 | +7.77% | $512.93M | vs NGNE |
| ALTAltimmune Inc. | 2.66 | -0.37% | $517.42M | vs NGNE |
| CBIOCrescent Biopharma Inc. | 13.49 | -0.59% | $501.11M | vs NGNE |
| ACRSAclaris Therapeutics Inc. | 3.40 | -8.11% | $500.48M | vs NGNE |
| MPLTMapLight Therapeutics Inc. | 9.36 | -3.41% | $520.19M | vs NGNE |
| OCSOculis Holding AG | 8.50 | -2.52% | $523.50M | vs NGNE |
Indexes, lists and sector
Neurogene stock FAQ
What is Neurogene's stock price today?
NGNE last traded at $25.87 as of Oct 7, 4:00 PM EDT, up 1.65% on the day. Prices are delayed at least 15 minutes.
Does Neurogene pay a dividend?
No. Neurogene does not currently pay a regular cash dividend.
Who is Neurogene's CEO?
Dr. Rachel L. McMinn Ph.D. is the chief executive officer of Neurogene Inc., which has about 131 employees.
Has NGNE ever split its stock?
Yes. The most recent NGNE stock split was a 1-for-4 split on Dec 19, 2023, one of 2 splits on record.
What is the NGNE 52-week high?
The 52-week high for NGNE is $43.66 and the 52-week low is $15.93. The stock is currently 40.7% below its high.